Speakers

Sven Kili

Chief Executive Officer • Antion Biosciences

Dr Sven Kili is Chief Executive Officer at Antion Biosciences, a Multiplex Cell Engineering company developing ‘Smart-Data’ driven in-vivo allogeneic cell therapies for underserved patients suffering from recalcitrant diseases. He was previously the Head of Development for the Cell and Gene Therapy division of GSK Rare Diseases where he led teams developing and commercialising Gene Therapies for a variety of rare genetic disorders including Strimvelis®, the first ex-vivo gene therapy to be approved for children with ADA-SCID; Wiskott – Aldrich syndrome (WAS); Metachromatic Leukodystrophy (MLD) and Beta-Thalassemia. Prior to this, he was Senior Director, Cell Therapy and Regenerative Medicine for Sanofi (Genzyme) Biosurgery where he led the clinical development, approval and commercialisation activities of the first combined ATMP product in the EU for MACI®.

Also Speaking

Steven B. Miller

Lung-I Cheng

Vice President, Cell and Gene Therapy • AmerisourceBergen

Yossi Schwartz

Professor, Pathology, Molecular and Cell Based Medicine at the Icahn School of Medicine • Mount Sinai Health System

Event Info

Image

Post-Event Report

Download the post-event report for Advanced Therapies Week 2023.
Image

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.